Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Calcium Folate for Reducing the Side Effects of Low-dose Methotrexate in Rheumatoid Arthritis: A Case Report

Author(s): Renzhu Liu, Qingzi Yan, Yixiang Hu and Xiang Liu*

Volume 19, Issue 1, 2024

Published on: 26 June, 2023

Page: [138 - 141] Pages: 4

DOI: 10.2174/1574886318666230612101111

Price: $65

Abstract

Introduction: We reported a patient with rheumatoid arthritis who received chronic methotrexate (MTX) therapy and experienced several adverse reactions like hemocytopenia and renal impairment. Under the monitoring of the therapeutic drug concentration, calcium folate and other measures were used to accelerate methotrexate excretion and eliminate adverse reactions.

Case Presentation: A 66-year-old man with rheumatoid arthritis received MTX and developed adverse effects of bone marrow suppression, like pancytopenia. He had a black stool, and he tested positive for occult blood, which was considered gastrointestinal bleeding. The blood MTX concentration reached 4.07 μmol/L, and leucovorin was administered to rescue the patient's life. Besides, hydration and alkaline urine were applied to quickly clear methotrexate inside the body.

Conclusion: Low-dose MTX has fewer adverse reactions but may cause bone marrow suppression- related side effects. Blood concentration monitoring can be used to guide the rescue of MTX poisoning.

Keywords: Rheumatoid arthritis, methotrexate, hemocytopenia, leucovorin, rescue, renal impairment.

« Previous Next »
Graphical Abstract

[1]
Chinese Rheumatology Association. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 2018; 57(4): 242-51.
[http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.04.004] [PMID: 29614581]
[2]
Chinese Association of Rheumatology and Immunology Physicians. Chinese expert-based consensus for methotrexate in rheumatic diseases. Zhonghua Nei Ke Za Zhi 2018; 57(10): 719-22.
[http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.10.005] [PMID: 30293331]
[3]
Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: A cohort of 28 patients. Autoimmun Rev 2014; 13(11): 1109-13.
[http://dx.doi.org/10.1016/j.autrev.2014.08.027] [PMID: 25172240]
[4]
Zhao Z, Hua Z, Luo X, et al. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother 2022; 150: 113074.
[http://dx.doi.org/10.1016/j.biopha.2022.113074] [PMID: 35658215]
[5]
Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: Relative importance of the de novo biopterin synthesis versus salvage pathways. J Biol Chem 2009; 284(41): 28128-36.
[http://dx.doi.org/10.1074/jbc.M109.041483] [PMID: 19666465]
[6]
CSCO. Expert consensus on high-dose methotrexate leucovorin rescue therapy for malignant tumors. Chin J Clin Oncol 2019; 46: 761-7.
[http://dx.doi.org/10.3969/j.issn.1000-8179.2019.15.748]
[7]
Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66(11): 1491-6.
[http://dx.doi.org/10.1136/ard.2006.069252] [PMID: 17412740]
[8]
Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet 2014; 29(1): 12-9.
[http://dx.doi.org/10.2133/dmpk.DMPK-13-RV-119] [PMID: 24284432]
[9]
Mori S, Hidaka M, Kawakita T, et al. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PLoS One 2016; 11(4): e0154744.
[http://dx.doi.org/10.1371/journal.pone.0154744] [PMID: 27128679]
[10]
Paul M, Hemshekhar M, Thushara RM, et al. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: Alleviation by N-acetylcysteine and N-acetylcysteine amide. PLoS One 2015; 10(6): e0127558.
[http://dx.doi.org/10.1371/journal.pone.0127558] [PMID: 26083398]
[11]
Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: A comprehensive literature review. Cureus 2022; 14(9): e29518.
[http://dx.doi.org/10.7759/cureus.29518] [PMID: 36312688]
[12]
Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: The MATRIX study. Rheumatology 2007; 47(3): 350-4.
[http://dx.doi.org/10.1093/rheumatology/kem370] [PMID: 18238787]
[13]
Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094-108.
[http://dx.doi.org/10.1016/S0140-6736(10)60826-4]
[14]
Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem 2018; 158: 502-16.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.027] [PMID: 30243154]
[15]
US Food and Drug Administration: Leucovorin. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/f198ab39-9394-4280-be44-93a88264a450/spl-doc?hl=Leucovorin [Accessed on: Sep 6, 2022].

Rights & Permissions Print Cite
Article Metrics
26
2
© 2024 Bentham Science Publishers | Privacy Policy